Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence

Journal of Bone and Mineral Research

Volumn 27, Issue 1, 2012, Pages 202-210

  Sampalis, John S ^a,b   Adachi, Jonathan D ^c   Rampakakis, Emmanouil ^a,b   Vaillancourt, Julie ^a   Karellis, Angela ^a   Kindundu, Christian ^d  

^a JSS Medical Research   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Novartis Pharmaceuticals Canada Inc   (Canada)

Author keywords

BISPHOSPHONATES; COMPLIANCE; FRACTURE; OSTEOPOROSIS; PERSISTENCE

Indexed keywords

ALENDRONIC ACID; CALCIUM CARBONATE; COLECALCIFEROL; ETIDRONIC ACID; RISEDRONIC ACID;

AGED; ARTICLE; CANADA; DATA BASE; FEMALE; FEMUR FRACTURE; FEMUR NECK FRACTURE; FOLLOW UP; FRAGILITY FRACTURE; HEALTH INSURANCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; DEMOGRAPHY; DIPHOSPHONATES; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; ONTARIO; OSTEOPOROTIC FRACTURES; PRESCRIPTION DRUGS; RISK FACTORS; TIME FACTORS;

EID: 84555189292     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.533     Document Type: Article

References (43)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun; 94 (6): 646-50.
2. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass. Washington, DC: National Osteoporosis Foundation; 2010.
3. Lorrain J, Paiement G, Chevrier N, Lalumiere G, Laflamme GH, Caron P, Fillion A,. Population demographics and socioeconomic impact of osteoporotic fractures in Canada. Menopause. 2003 May; 10 (3): 228-34. (Pubitemid 36706308)
4. US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
5. International Osteoporosis Foundation. Osteoporosis in the workplace: the social, economic and human costs of osteoporosis on employees, employers and governments. Liege, Belgium: WHO Collaborating Centre; 2003.
6. Goeree RG, Pettitt DB, Cuddy L, et al. An assessment of the burden of illness due to osteoporosis in Canada. J Soc Obstet Gynaecol Can. 1996; 18 (Suppl): 15-24.
7. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A,. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 Mar; 22 (3): 465-75. (Pubitemid 46797130)
8. Colon-Emeric C, Kuchibhatla M, Pieper C, Hawkes W, Fredman L, Magaziner J, Zimmerman S, Lyles KW,. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003 Nov; 14 (11): 879-83. (Pubitemid 38009526)
9. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA,. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999 Mar 13; 353 (9156): 878-82. (Pubitemid 29126875)
10. Gold DT,. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone. 1996 Mar; 18 (3 Suppl): 185S-9S. (Pubitemid 126352529)
11. Adachi JD, Ioannidis G, Pickard L, Berger C, Prior JC, Joseph L, Hanley DA, Olszynski WP, Murray TM, Anastassiades T, et al. The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int. 2003 Nov; 14 (11): 895-904. (Pubitemid 38009529)
12. Adachi JD, Adami S, Gehlbach S, Anderson FA Jr, Boonen S, Chapurlat RD, Compston JE, Cooper C, Delmas P, Diez-Perez A, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc. 2010 Sep; 85 (9): 806-13.
13. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ. 2009 Sep 1; 181 (5): 265-71.
14. Sawka AM, Thabane L, Papaioannou A, Gafni A, Ioannidis G, Papadimitropoulos EA, Hopman WM, Cranney A, Hanley DA, Pickard L, et al. Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int. 2005 Dec; 16 (12): 1836-40. (Pubitemid 41790897)
15. Liebman M,. Awakening the silent osteoporosis market. Med Marketing Media. 2002 Apr; 37 (4): 56-62.
16. Wasnich RD, Miller PD,. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000 Jan; 85 (1): 231-6. (Pubitemid 32268819)
17. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ,. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993 May; 91 (5): 2004-11. (Pubitemid 23141472)
18. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004 Mar 18; 350 (12): 1189-99. (Pubitemid 38339363)
19. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 Dec 7; 348 (9041): 1535-41. (Pubitemid 26411651)
20. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999; 9 (5): 461-8. (Pubitemid 29231740)
21. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002 Aug; 87 (8): 3609-17. (Pubitemid 34879503)
22. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11 (1): 83-91. (Pubitemid 30099515)
23. Cramer JA, Amonkar MM, Hebborn A, Altman R,. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005 Sep; 21 (9): 1453-60. (Pubitemid 41368578)
24. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J,. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004 Jul 15; 48 (3): 271-87. (Pubitemid 38781153)
25. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL,. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009 Feb; 122 (2 Suppl): S3-13.
26. Recker RR, Gallagher R, MacCosbe PE,. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005; 80 (7): 856-61. (Pubitemid 40911458)
27. Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney TP, Prestwood K,. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt). 2003 Dec; 12 (10): 1037-45. (Pubitemid 38072422)
28. Sheehy O, Kindundu CM, Barbeau M, LeLorier J,. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int. 2009 Aug; 20 (8): 1369-76.
29. Penning-van Beest FJA, Erkens JA, Olson M, Herings RMC,. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008 Mar 31; 24 (5): 1337-44. (Pubitemid 351741565)
30. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C,. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004; 15 (12): 1003-8. (Pubitemid 40064656)
31. Huybrechts KF, Ishak KJ, Caro JJ,. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006; 38 (6): 922-8. (Pubitemid 44498580)
32. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S,. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81 (8): 1013-22. (Pubitemid 44175011)
33. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E,. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008 Sep; 23 (9): 1435-41.
34. Briesacher BA, Andrade SE, Kahler KH, Yood RA,. Economic impact of the previous year's adherence with bisphosphonates. Abstracts of the 28th Annual Meeting of the American Society for Bone and Mineral Research, September 15-19, 2006, Philadelphia, Pennsylvania, USA. (Abstract SA300). J Bone Miner Res. 2006; 21 (Suppl 1): S2-460.
35. Briesacher BA, Andrade SE, Yood RA, Kahler KH,. Consequences of poor compliance with bisphosphonates. Bone. 2007; 41 (5): 882-7. (Pubitemid 47593009)
36. Curtis JR, Westfall A, Cheng H, Delzell E, Lyles K, Saaq KG,. Longitudinal patterns of adherence with bisphosphonates. Abstracts of the 29th Annual Meeting of the American Society for Bone and Mineral Research, September 16-19, 2007, Honolulu, Hawaii, USA. (Abstract M444). J Bone Miner Res. 2007; 22 (Suppl 1): S2-510.
37. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM,. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008; 19 (4): 511-7.
38. Melo M, Qiu F, Sykora K, Juurlink D, Laupacis A, Mamdani M,. Persistence with bisphosphonate therapy in older people. J Am Geriatr Soc. 2006; 54 (6): 1015-6. (Pubitemid 43847052)
39. Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F,. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007; 23 (3): 585-94. (Pubitemid 46456906)
40. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM,. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin. 2006; 22 (9): 1757-64. (Pubitemid 44449232)
41. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM,. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010 Nov; 21 (11): 1943-51.
42. Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes JC, Perreault S,. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol. 2008; 66 (1): 117-27. (Pubitemid 351822168)
43. Sheehy O, Kindundu CM, Barbeau M, Lelorier J,. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int. 2009; 20 (8): 1369-76.